One of the companies wanting to be part of the upcoming U.S. launch of Humira biosimilars is instead exploring options to raise additional capital so it can continue advancing its biosimilar pipeline ...

AbbVie Inc.’sABBV0.99%increase; green up pointing triangle arthritis therapy Humira is set to face its first competition in the U.S. from a near-identical copycat, the end of the exclusive run of what ...

Optum Rx will add two more Humira biosimilars to its formulary later this summer. The pharmacy benefit manager—one of the three largest in the market—will place Boehringer Ingelheim's Cyltezo and ...

Humira is the best-selling prescription drug in the world. You may have seen the commercials. Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, another with ...

AbbVie’s top job today centers on developing new sources of revenue out of the fear that biosimilars to its megablockbuster Humira will cause a precipitous sales decline starting in 2023. But after ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...